ATRS
Antares Pharma, Inc.
stockNASDAQ

Latest News

Nov 13, 2026

10:00 PM ESTKaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm · NewMediaWire

05:40 PM ESTKaplan Fox Deadline Alert: Yiren Digital Ltd. (NYSE: YRD) Investors Have Until December 28, 2026 to Seek a Lead Plaintiff Role · NewMediaWire

05:30 PM ESTKaplan Fox Announces a Securities Class Action Filed Against Gildan Activewear Inc. (NYSE: GIL) Lead Plaintiff Deadline is December 14, 2026 · NewMediaWire

05:20 PM ESTKaplan Fox Encourages Investors of Millrose Properties, Inc. (NYSE: MRP) to Contact the Firm Before the Securities Class Action Deadline on December 8, 2026 · NewMediaWire

05:10 PM ESTKaplan Fox Alerts Duolingo, Inc. (NASDAQ: DUOL) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is December 7, 2026 · NewMediaWire

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.